Eosinophils from patients with type 1 diabetes mellitus express high level of myeloid alpha-defensins and myeloperoxidase

Cellular Immunology

Volumn 273, Issue 2, 2012, Pages 158-163

  Neuwirth, Aleš ^a   Dobeš, Jan ^a   Oujezdská, Jana ^a   Ballek, Ondřej ^a   Benešová, Martina ^a   Šumník, Zdeněk ^b   Včeláková, Jana ^b   Koloušková, Stanislava ^b   Obermannová, Barbora ^b   Kolář, Michal ^a   Štechová, Kateřina ^b   Filipp, Dominik ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Defensin; Eosinophil; Granulocyte; Myeloperoxidase; Type 1 diabetes

Indexed keywords

ALPHA DEFENSIN; CD14 ANTIGEN; CD15 ANTIGEN; EOSINOPHIL PEROXIDASE; MESSENGER RNA; MYELOID ALPHA DEFENSIN; MYELOPEROXIDASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CELL STRUCTURE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; EOSINOPHIL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UPREGULATION;

ADOLESCENT; ADULT; ALPHA-DEFENSINS; ANTIGENS, CD14; ANTIGENS, CD15; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; EOSINOPHILS; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; INSULIN-SECRETING CELLS; PEROXIDASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84857195672     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.12.001     Document Type: Article

References (26)

1. Von Herrath M., Sanda S., Herold K. Type 1 diabetes as a relapsing-remitting disease?. Nat. Rev. Immunol. 2007, 7:988-994.
2. Todd J.A. Etiology of type 1 diabetes. Immunity 2010, 32:457-467.
3. Lehuen A., Diana J., Zaccone P., Cooke A. Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol. 2010, 10:501-513.
4. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 2003, 3:710-720.
5. Borregaard N., Sorensen O.E., Theilgaard-Monch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 2007, 28:340-345.
6. Papayannopoulos V., Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol. 2009, 30:513-521.
7. Selsted M.E., Ouellette A.J. Mammalian defensins in the antimicrobial immune response. Nat. Immunol. 2005, 6:551-557.
8. Nassar H., Lavi E., Akkawi S., Bdeir K., Heyman S.N., Raghunath P.N., et al. Alpha-Defensin: link between inflammation and atherosclerosis. Atherosclerosis 2007, 194:452-457.
9. Joseph G., Tarnow L., Astrup A.S., Hansen T.K., Parving H.H., Flyvbjerg A., et al. Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. J. Clin. Endocrinol. Metab. 2008, 93:1470-1475.
10. Sthoeger Z.M., Bezalel S., Chapnik N., Asher I., Froy O. High alpha-defensin levels in patients with systemic lupus erythematosus. Immunology 2009, 127:116-122.
11. Diagnosis and classification of diabetes mellitus. Diabetes Care 34 (Suppl. 1) (2011) S62-S69.
12. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
13. Driss V., Legrand F., Hermann E., Loiseau S., Guerardel Y., Kremer L., et al. TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins. Blood 2009, 113:3235-3244.
14. Schagger H. Tricine-SDS-PAGE. Nat. Protoc. 2006, 1:16-22.
15. Team RDC, R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria ISBN 3-900051-07-0, 2010.
16. Fraley C., Raftery A.E. Model-based clustering, discriminant analysis and density estimation. J. Am. Stat. Assoc. 2002, 97:611-631.
17. Schwarz G. Estimating the dimension of a model. Ann. Statist. 1978, 6:461-464.
18. Akaike H. A new look at the statistical model identification. IEEE Trans. Autom. Control 1974, 19:716-723.
19. Sabroe I., Jones E.C., Usher L.R., Whyte M.K., Dower S.K. Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J. Immunol. 2002, 168:4701-4710.
20. Schefzyk M., Bruder M., Schmiedl A., Stephan M., Kapp A., Wedi B., et al. Eosinophil granulocytes: functional differences of a new isolation kit compared to the isolation with anti-CD16-conjugated MicroBeads. Exp. Dermatol. 2009, 18:653-655.
21. Gruart V., Truong M.J., Plumas J., Zandecki M., Kusnierz J.P., Prin L., et al. Decreased expression of eosinophil peroxidase and major basic protein messenger RNAs during eosinophil maturation. Blood 1992, 79:2592-2597.
22. Hakansson L., Bjornsson E., Janson C., Schmekel B. Increased adhesion to vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 of eosinophils from patients with asthma. J. Allergy Clin. Immunol. 1995, 96:941-950.
23. Hakkim A., Furnrohr B.G., Amann K., Laube B., Abed U.A., Brinkmann V., et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA 2010, 107:9813-9818.
24. Nagase H., Okugawa S., Ota Y., Yamaguchi M., Tomizawa H., Matsushima K., et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J. Immunol. 2003, 171:3977-3982.
25. Von Herrath M. Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapies. Diabetes 2009, 58:2-11.
26. Hessner M.J., Wang X., Meyer L., Geoffrey R., Jia S., Fuller J., et al. Involvement of eotaxin, eosinophils, and pancreatic predisposition in development of type 1 diabetes mellitus in the BioBreeding rat. J. Immunol. 2004, 173:6993-7002.